| 48.69 1.19 (2.51%) | 10-15 12:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 57.81 | 1-year : | 67.52 |
| Resists | First : | 49.5 | Second : | 57.81 |
| Pivot price | 46.63 |
|||
| Supports | First : | 44.97 |
Second : | 42.18 |
| MAs | MA(5) : | 48.21 |
MA(20) : | 46.02 |
| MA(100) : | 40.15 |
MA(250) : | 42.17  |
|
| MACD | MACD : | 1.8 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 85.1 |
D(3) : | 83 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 62.4 | Low : | 29.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RVMD ] has closed below upper band by 14.9%. Bollinger Bands are 28.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 48.83 - 49.08 | 49.08 - 49.3 |
| Low: | 46.89 - 47.18 | 47.18 - 47.43 |
| Close: | 47.03 - 47.52 | 47.52 - 47.93 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Mon, 13 Oct 2025
Revolution Medicines (RVMD) Stock Analysis: Unveiling a 56% Potential Upside Amidst Robust Buy Ratings - DirectorsTalk Interviews
Tue, 07 Oct 2025
Did Leadership Moves Just Shift Revolution Medicines' (RVMD) Investment Narrative Ahead of Key Launches? - Yahoo Finance
Mon, 06 Oct 2025
Revolution Medicines, Inc. (RVMD) Stock Analysis: Unveiling a 61.57% Upside Potential for Investors - DirectorsTalk Interviews
Sat, 04 Oct 2025
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Thu, 02 Oct 2025
Revolution Medicines, Inc. (RVMD) Insider Sells Shares - Yahoo Finance
Mon, 29 Sep 2025
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 187 (M) |
| Shares Float | 159 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 103.9 (%) |
| Shares Short | 17,970 (K) |
| Shares Short P.Month | 16,530 (K) |
| EPS | -4.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.5 % |
| Return on Equity (ttm) | -46.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.24 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -685 (M) |
| Levered Free Cash Flow | -396 (M) |
| PE Ratio | -10.84 |
| PEG Ratio | 0 |
| Price to Book value | 4.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|